B+
Bull case
30%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
MIRM
MirumCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$94.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$59.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+73.3
Score
AI commentary
Company news is favorable, but the October 1 $83.92 packet anchor is about 6.4% below the prior baseline's $89.70 anchor; the two observations alone do not establish an event-day reaction or its cause. Post-readout analyst target changes are mixed in magnitude and broader estimate revisions were not verified. Numeric sentiment fields set to zero denote unavailable measurements, not neutral readings; social coverage is absent.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-28eventBrelovitug Phase 3 AZURE-1 resultMedium impact
On September 28, AZURE-1 met its Week 24 composite endpoint: response was 56% and 45% in the two brelovitug arms versus 0% with delayed treatment (p<0.0001 for both). This strengthens the HDV program, but a second pivotal readout remains outstanding. [#IR-2026-09-28] Mirum release
2026-10-31catalystATEBRIOZ U.S. launchMedium impact
Following FDA approval for FOP patients aged 12 and older, Mirum expects U.S. availability in October. Access and initial uptake—not approval—are now the key uncertainties. The reported Week 24 reduction in new HO lesion volume is also supported by the September 28 SEC filing excerpt. [#8-K-2026-09-28] [#IR-2026-09-25] Mirum/Incyte release
2026-12-31eventBrelovitug AZURE-4 topline dataHigh impact
Mirum expects Q4 2026 results from AZURE-4, the second pivotal HDV study intended to support U.S. registration. Consistency with AZURE-1 efficacy and safety is the principal near-term binary risk. [#IR-2026-09-28] Mirum release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology